Britain and America have hammered out a key trade agreement that will maintain zero import taxes on British pharmaceutical products going into the American market.
Key Provisions of the Pact
As part of the deal, the UK has agreed to raise spending on drugs through the NHS. This move secures that duties on these crucial exports will remain at nothing for a duration of 36 months.
This deal comes after recent threats to dramatically increase duties on patented drug products, with figures discussed up to double the cost.
"This deal with the United Kingdom strengthens the worldwide climate for new treatments and introduces long-overdue fairness to U.S.–U.K. pharmaceutical trade," an announcement declared.
Commercial Significance
Drugs represent one of the the United Kingdom's biggest goods shipped to the America, which is easily the largest destination for leading UK drugmakers.
Trade data reveal that in the 12 months to the end of last September, the UK exported medicines totaling over eleven billion pounds to the US. This value represented 17.4% of all goods exports in that period.
"This guarantee protects work, increases funding and facilitates the UK to emerge as a global hub for life sciences," the Business and Trade Secretary commented.
Key UK Commitments
The agreement entails several notable changes from the UK:
- Higher Cost Ceiling: The UK will raise the cost ceiling at which it deems new therapies to be prohibitively costly by 25%.
- Higher Drug Budget: There is a goal to increase overall NHS spending on treatments from 0.3% of Gross Domestic Product to 0.6 percent over the following ten-year period.
- Rebate Cap: The percentage manufacturers must pay back to the NHS to prevent overspending will be limited at fifteen percent. In the past, refunds exceeded 20%.
Broader Context
The deal follows a ongoing tension between the pharmaceutical industry and the British authorities over spending levels and approval rates.
This friction were exacerbated by arguments that American patients were paying a premium for the equivalent treatments than consumers in the UK and Europe.
Over the last 18 months, several major drug company projects in the UK have been halted or abandoned, while major funding commitments have been pledged toward American operations.
A senior figure acknowledged that the NHS needed to invest a greater share on treatments, noting that its spending on drugs had shrunk as a proportion of its total funding over the last ten years.
